explore -WSS

explore

author：knowledge 2025-10-01 11:46:07 - browse：16

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： CDC launches VaccineFinder tool to locate Covid

leisure time

WSS

Elisabeth Bik tackles the widespread issue of research misconduct

5 ways to address the shortage of health care workers

FTX founder Sam Bankman

Childhood vaccination ad campaign launches in the U.K.

Sage's campaign to raise awareness of postpartum depression hits a nerve

NEJM study measures Covid brain fog, impact on IQ

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

Walensky prepares to leave CDC — and Congress — behind

STAT Madness 2024: Meet the contenders

Dobbs anniversary: the lost opportunity of abortion as health care

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Redefining sustainability for the pharmaceutical industry

As demand for Covid shots wanes, Moderna seeks its next success

Discs beat pads, tampons for heavy menstrual flow, new study shows

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CDC panel: People 65 and older should get a Covid spring booster shot

Wikipedia

Cholera vaccine supplies dangerously low, outbreaks surging

Ohio train derailment: Experts on toxic chemical risks

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

Medicare isn't yet testing food as medicine

Wegovy cuts risk of cardiovascular events by 20%, study finds

Ohio train derailment: Experts on toxic chemical risks

focus

explore

leisure time

Wikipedia